HOXA5 was observed to be significantly up-regulated in GBM (WHO grade IV) compared with low-grade glioma (LGG) samples (WHO grade III and WHO grade II) in the TCGA and CGGA cohorts (P <0.001, respectively; Figure 1A). This evidence concerns the gene HOXA5 and central nervous system cancer.